Y Intercept Hong Kong Ltd Acquires New Position in Nautilus Biotechnology, Inc. $NAUT

Y Intercept Hong Kong Ltd bought a new stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 224,456 shares of the company’s stock, valued at approximately $163,000. Y Intercept Hong Kong Ltd owned 0.18% of Nautilus Biotechnology as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. purchased a new stake in Nautilus Biotechnology in the first quarter valued at approximately $194,000. Clarius Group LLC grew its position in shares of Nautilus Biotechnology by 22.4% during the second quarter. Clarius Group LLC now owns 1,060,460 shares of the company’s stock worth $769,000 after acquiring an additional 193,874 shares during the last quarter. Nuveen LLC acquired a new position in shares of Nautilus Biotechnology in the 1st quarter valued at $167,000. Acadian Asset Management LLC increased its holdings in shares of Nautilus Biotechnology by 468.3% in the 1st quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock valued at $51,000 after acquiring an additional 50,871 shares during the period. Finally, Callan Family Office LLC purchased a new stake in Nautilus Biotechnology in the 2nd quarter valued at $35,000. Hedge funds and other institutional investors own 50.71% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Nautilus Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday. Two equities research analysts have rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell” and a consensus target price of $2.13.

Insider Activity at Nautilus Biotechnology

In other news, CEO Sujal M. Patel bought 83,500 shares of the stock in a transaction dated Monday, September 8th. The shares were acquired at an average price of $0.68 per share, with a total value of $56,780.00. Following the completion of the acquisition, the chief executive officer directly owned 10,341,721 shares in the company, valued at approximately $7,032,370.28. The trade was a 0.81% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have acquired 220,000 shares of company stock valued at $147,635. 41.10% of the stock is currently owned by company insiders.

Nautilus Biotechnology Price Performance

NASDAQ:NAUT opened at $1.51 on Monday. The firm’s fifty day moving average price is $0.98 and its 200 day moving average price is $0.83. Nautilus Biotechnology, Inc. has a 1-year low of $0.62 and a 1-year high of $2.68. The firm has a market cap of $190.73 million, a price-to-earnings ratio of -3.02 and a beta of 1.54.

Nautilus Biotechnology Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.